Patents Examined by Ben S Michelson
  • Patent number: 10011574
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: July 3, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • Patent number: 10010880
    Abstract: A new class of ligands derived from benzo[h]quinoline are described and these ligands are used to prepare several novel transition metal complexes. The complexes are preferably of the group VIII transition metals iron, ruthenium or osmium, with the benzo[h]quinolone ligands acting as tridentate ligands. The complexes described are proved to be very active catalysts for the reduction of ketones and aldehydes to alcohols, via hydrogen transfer and hydrogenation reactions. These compounds hence can be usefully employed as catalysts in said reduction reactions.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 3, 2018
    Assignee: UNIVERSITA' DEGLI STUDI DI UDINE
    Inventors: Pierluigi Rigo, Walter Baratta, Katia Siega, Giorgio Adolfo Chelucci, Maurizio Ballico, Santo Magnolia
  • Patent number: 9981043
    Abstract: The invention provides analgesic conjugates having a mu opioid receptor agonist linked to a mGluR5 antagonist, and to methods for producing analgesia using such compounds.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 29, 2018
    Assignee: Regents of the University of Minnesota
    Inventors: Philip Portoghese, Akgun Eyup
  • Patent number: 9938255
    Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 10, 2018
    Assignee: VPS-3, Inc.
    Inventors: William J. Hoekstra, Christopher M. Yates
  • Patent number: 9924721
    Abstract: Malonic ester derivatives of the formula (I) in which the symbols A1, A2, Y, R10, p, X, R2, G, Q, L2 and R1 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: March 27, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Stefan Hillebrand, Matthias Riedrich, Sebastian Hoffmann, Mark James Ford, Joachim Telser, Mazen Es-Sayed, Guenter Hoemberger, Pierre Wasnaire, Ulrike Wachendorff-Neumann, Tomoki Tsuchiya, Valerie Toquin
  • Patent number: 9925528
    Abstract: The invention provides simple small molecule, non-heme iron catalyst systems with broad substrate scope that can predictably enhance or overturn a substrate's inherent reactivity preference for sp3-hybridized C—H bond oxidation. The invention also provides methods for selective aliphatic C—H bond oxidation. Furthermore, a structure-based catalyst reactivity model is disclosed that quantitatively correlates the innate physical properties of the substrate to the site-selectivities observed as a function of the catalyst. The catalyst systems can be used in combination with oxidants such as hydrogen peroxide to effect highly selective oxidations of unactivated sp3 C—H bonds over a broad range of substrates.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 27, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: M. Christina White, Paul E. Gormisky
  • Patent number: 9908858
    Abstract: The invention relates to a method for producing a hydrazine of general formula (I) and the pharmaceutically acceptable salts thereof from an amine of formula (II), characterised in that said method uses a urea of formula (III) as a synthesis intermediate.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 6, 2018
    Assignee: AVIRAGEN THERAPEUTICS, INC.
    Inventors: Marta Blumenfeld, Delphine Compere, Marco A. Ciufolini
  • Patent number: 9902743
    Abstract: A composition and method are disclosed for capturing CO2. A pollutant/greenhouse gas can be converted into a valuable organic compound using a nontoxic reducing agent. CO2 may be economically captured from the atmosphere, from products of combustion, or from byproducts of various chemical processes. The method reduces CO2 in a three-step reaction cycle, in which a binuclear metal-organic compound converts CO2 to oxalate in a redox cycle under mild conditions.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: February 27, 2018
    Inventors: Andrew W. Maverick, Uttam R. Pokharel, Frank R. Fronczek
  • Patent number: 9890121
    Abstract: The present invention relates to a process for the preparation of Compound (A): wherein the process comprises contacting atazanavir base (Compound (II)) with sulphuric acid in a combination of two or more solvents and isolating compound (A). The present invention also relates to substantially pure Compound (A), and to Compound (A) devoid of mesityl oxide impurity.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: February 13, 2018
    Assignee: Cipla Limited
    Inventors: Rajendra Narayanrao Kankan, Srinivas Laxminarayan Pathi, Venugopalarao Chinimilli
  • Patent number: 9884822
    Abstract: Disclosed herein is a cost effective and environmentally friendly process to prepare 1-hydroxy-6-substituted pyridones from 2,6-dichloropyridine.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: February 6, 2018
    Assignee: Arch Chemicals, Inc.
    Inventors: Rahim Hani, David A. Steele, John Joseph Jardas
  • Patent number: 9884824
    Abstract: Methods of producing a sulfilimine compound, such as N-cyano-S-methyl-S-[1-(6-trifluoromethyl-3-pyridinyl)ethyl]sulfilimine or other substituted sulfilimine compound. The method includes combining a sulfide compound, cyanamide, a hypochlorite compound, and a base, and oxidizing the sulfide compound to form the sulfilimine compound. The sulfide compound may include a 2-trifluoromethyl-5-(1-substituted)alkyl-thiopyridine compound. The base may include sodium hydroxide. A buffer, such as a phosphate buffer, may, optionally, be used in the reaction.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 6, 2018
    Assignee: Dow AgroSciences LLC
    Inventor: Timothy J. Adaway
  • Patent number: 9879024
    Abstract: The present invention provides a new forms of (R)-N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 30, 2018
    Assignees: Progenics Pharmaceuticals., Inc., Wyeth, LLC
    Inventors: Valeriya N. Smolenskaya, Kadum A. Al Shareffi, Julio Perez, Syed M. Shah, Thomas A. Boyd
  • Patent number: 9873691
    Abstract: The disclosure relates to Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein Ar1, Ar2, L1, L2, X, R3, R22, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I), and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: January 23, 2018
    Assignee: Purdue Pharma L.P.
    Inventor: Jianming Yu
  • Patent number: 9873679
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: January 23, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth A. Jurica, Zhenqiu Hong
  • Patent number: 9854805
    Abstract: The present invention provides a composition for controlling pests having an excellent control efficacy on pests. A composition for controlling pests comprising a compound represented by the formula (1): wherein each of symbols are the same as defined in the Description, or N-oxide thereof; and a compound represented by the formula (2): wherein each of symbols are the same as defined in the Description; shows an excellent controlling efficacy on pests.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 2, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Chie Shimizu, Masashi Kamezaki, Yoshihiko Nokura
  • Patent number: 9844773
    Abstract: The present application describes a novel type of picolinamide-cinchona organocatalyst that allows for the successful transformation of ketimines to chiral amines with very high enantioselectivities and with the highest TOFs reported for any particular organocatalyst to date. These organocatalysts have also been immobilized to a variety of solid supports, including magneto-nanoparticles.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 19, 2017
    Assignee: UNIVERSIDADE DE EVORA
    Inventors: Anthony Burke, Pedro Miguel Cambeiro Barrulas
  • Patent number: 9801872
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 31, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • Patent number: 9776969
    Abstract: Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, {[(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibittors or for treating conditions wherein prolyl hydroxylase inhibition is desired.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: October 3, 2017
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Christopher M. Lanthier, Boris Gorin, Jan Oudenes, Craig Edward Dixon, Alan Quigbo Lu, James Densmore Copp, John Michael Janusz
  • Patent number: 9777005
    Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa? or —N?; X2 is —CRb? or —N?; X3 is —CRc= or —N?; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: October 3, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Shinkichi Suzuki, Masami Yamada, Makoto Kamata, Takuto Kojima, Ikuo Fujimori, Kenichiro Shimokawa
  • Patent number: 9776966
    Abstract: Provided herein are processes and intermediate compounds useful for the preparation of 2-carboxamide cycloamino urea derivatives, and useful intermediates therefore.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: October 3, 2017
    Assignee: Novartis AG
    Inventors: Bernhard Erb, Isabelle Sylvie Gallou, Florian Karl Kleinbeck